Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.